Humacyte, Inc. appointed Scott Coward and Paul Kuznik to its Board of Directors on September 22, 2026. Mr. Coward joins as a Class I director with a term expiring in 2028 and serves on the Audit Committee; he previously served as Chief Legal Officer at Exact Sciences Corporation. Mr. Kuznik joins as a Class II director with a term expiring in 2029 and serves on the Commercial Committee; he is a former CEO of Bolton Medical and President of Terumo Aortic North America. Each director receives an annual cash retainer of $50,000, committee fees of $5,000, and options to purchase 125,000 shares. Humacyte operates in the biotechnology industry, developing bioengineered human tissues for medical applications.
